Abstract
Hematological malignancies comprise over a hundred different types of cancers and account for around 6.5% of all cancers. Despite the significant improvements in diagnosis and treatment, many of those cancers remain incurable. In recent years, cancer cell-based therapy has become a promising approach to treat those incurable hematological malignancies with striking results in different clinical trials. The most investigated, and the one that has advanced the most, is the cell-based therapy with T lymphocytes modified with chimeric antigen receptors. Those promising initial results prepared the ground to explore other cell-based therapies to treat patients with blood cancer. In this review, we want to provide an overview of the different types of cell-based therapies in blood cancer, describing them according to the cell source.
Highlights
Hematologic malignancies are the fourth-most common type of cancer, with a higher incidence in older adults [1]
As the function of Natural Killer (NK) cells relies on the balance of signals from inhibitory and activating receptors that recognize a specific pattern of ligands in healthy cells and diseased ones, the infusion of allogeneic NK cells is safe and does not cause unwanted and deleterious GvHD [56], laying the foundation for the development of another universal, off-the-shelf cancer cell-based immunotherapy
Thrombocytes, are non-nucleated cell fragments. Their primary function is the formation of clots after blood vessel injury to stop bleeding and to maintain vascular integrity. Harnessing their capacity to adhere to tumor cells [97], platelets have been studied as a vehicle to deliver therapeutic drugs to cancer cells [98]
Summary
Benjamin Motais 1,2 , Sandra Charvátová 1,2 , Matouš Hrdinka 1,3 , Michal Šimíček 1,2,3 , Tomáš Jelínek 1,2,3 , Tereza Ševčíková 1,2,3 , Zdeněk Kořístek 1,3 , Roman Hájek 1,3 and.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.